Articles in Stocks

Zacks.com

OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog

OncoGenex Pharmaceuticals, Inc.  ( OGXI ) reported a loss of 59 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 44 cents and the year ago loss... Read >>

Zacks.com

Synageva's Q1 Loss Narrower than Expected - Analyst Blog

Synageva BioPharma Corp. ( GEVA ) reported first quarter 2014 loss of $1.16 per share, wider than the year ago loss of 54 cents per share, but narrower than the Zacks Consensus Estimate of a... Read >>

Zacks.com

Embraer SA Beats on Q1 Earnings - Analyst Blog

Embraer SA' s ( ERJ ) first quarter 2014 earnings of 34 cents per American Depository Shares (ADS) spiked 78.9% from 19 cents per ADS in the prior year quarter. The reported figure also beat the... Read >>

Zacks.com

Alpha Natural Resources Reports Earnings, Beats Estimates - Analyst Blog

Coal producer Alpha Natural Resources ( ANR ) reported earnings of 7 cents per share for the first quarter of 2014, surpassing the Zacks Consensus Estimate of a loss of 58 cents by a wide... Read >>

Zacks.com

Avanir Wins Lawsuit, Shares Up - Analyst Blog

Shares of Avanir Pharmaceuticals, Inc. ( AVNR ) soared 45.6% after the company announced that the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit... Read >>

Zacks.com

CACI Q3 Earnings Way Ahead of Estimates - Analyst Blog

Technical service provider CACI International Inc. ( CACI ) reported relatively modest third quarter fiscal 2014 results with a focused market driven strategy and strong cash flow. Adjusted... Read >>

Zacks.com

Lazard Earnings Beat Ests, Revs Up - Analyst Blog

Driven by top line growth, Lazard Ltd. 's ( LAZ ) first quarter 2014 adjusted earnings came in at 61 cents per share, easily beating the Zacks Consensus Estimate of 55 cents. Moreover, this... Read >>

Zacks.com

Avon Q1 Earnings Disappoint, Declares Dividend - Analyst Blog

The global beauty company, Avon Products Inc. ( AVP ) reported adjusted earnings of 12 cents per share for first quarter 2014, below the Zacks Consensus Estimate of 20 cents and plunged 50% from... Read >>

Zacks.com

CRL for The Medicines Co.'s Cangrelor - Analyst Blog

The FDA issued a Complete Response Letter (CRL) to The Medicines Company 's ( MDCO ) New Drug Application (NDA) for cangrelor. The company is looking to get cangrelor approved for the reduction... Read >>

Zacks.com

Equity Residential Q1 FFO In Line - Analyst Blog

Equity Residential 's ( EQR ) normalized funds from operations (FFO) per share in first quarter 2014 reached 71 cents, in line with the Zacks Consensus Estimate and within the company's guided... Read >>